Utilization, Spending, and Price Trends for Benzodiazepines in the US Medicaid Program: 1991-2009
- 27 March 2012
- journal article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 46 (4), 503-512
- https://doi.org/10.1345/aph.1q618
Abstract
Background: Although it is well-known that drug costs in the US have risen precipitously over the last 25 years, what is much less appreciated is how this rise in cost has occurred across so many seemingly distinct drug markets. Objective: To describe trends in the utilization, spending, and average per-prescription cost of benzodiazepines individually, in subgroups, and overall, in the Medicaid program. Medicaid has been the primary public payer for benzodiazepines over the past 2 decades. Methods: A retrospective, descriptive analysis was performed for the years 1991-2009 using the publicly available national Summary Files from the Medicaid State Drug Utilization Data maintained by the Centers for Medicare & Medicaid Services. Quarterly prescription counts and reimbursement amounts were calculated for all benzodiazepines reimbursed by Medicaid. Average per-prescription spending as a proxy for drug price was found by dividing reimbursement by the number of prescriptions. Results: Prescriptions for benzodiazepines among Medicaid beneficiaries increased from 8.0 million in 1991 to 17.1 million in 2009. Expenditures rose from $131.6 million to $171.1 million over the same time period. The average per-prescription price was a little over $10 in 2009. Whereas utilization of intermediate- and long-acting agents increased over time, prescriptions for short-acting drugs fell from 1.1 million to 0.3 million (1991-2009). The percentage rise in Medicaid spending on benzodiazepines since 1991 (30.0%) was less than the general rate of inflation (57.5%), as measured by the percentage change in the consumer price index over the same time period. Conclusions: Relative to the rise in the number of Medicaid beneficiaries (more than doubled over the study period), there is no evidence of an extraordinary rise in the utilization of benzodiazepines. Moreover, both nominal and real average prices of benzodiazepines have fallen, primarily because of generic entry over the last 2 decades.Keywords
This publication has 18 references indexed in Scilit:
- ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008Journal of Managed Care Pharmacy, 2010
- The Pharmacologic Treatment of Anxiety DisordersThe Journal of Clinical Psychiatry, 2010
- Utilization, price, and spending trends for antidepressants in the US Medicaid programResearch in Social and Administrative Pharmacy, 2008
- Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmesJournal of Medical Economics, 2008
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Price and Market-Share Competition of Anti-Ulcer Gastric Medications in the Ohio Medicaid MarketInternational Journal of Pharmaceutical Medicine, 2004
- Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older AdultsArchives of Internal Medicine, 2003
- GABA mechanisms and sleepNeuroscience, 2002
- A New Benzodiazepine PharmacologyJournal of Pharmacology and Experimental Therapeutics, 2002
- Defining patterns of benzodiazepine use in older adults.Journal of Geriatric Psychiatry and Neurology, 2000